Oncotarget

Research Papers:

Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors

Albert A. Antolín, Jordi Mestres _

PDF |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2014; 5:3023-3028. https://doi.org/10.18632/oncotarget.1814

Metrics: PDF 1825 views  |   HTML 1392 views  |   ?  


Abstract

Albert A. Antolín1, and Jordi Mestres1

1 Systems Pharmacology, Research Program on Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Catalonia, Spain

Correspondence:

Jordi Mestres, email:

Keywords: PARP inhibitors, off-target pharmacology, kinase profiling, drug combinations, biomarkers

Received: January 10, 2014 Accepted: March 9, 2014 Published: March 10, 2014

Abstract

PARP inhibitors hold promise as a novel class of targeted anticancer drugs. However, their true mechanism of action is still not well understood following recent reports that show marked differences in cellular effects. Here, we demonstrate that three PARP drug candidates, namely, rucaparib, veliparib, and olaparib, have a clearly different in vitro affinity profile across a panel of diverse kinases selected using a computational approach that relates proteins by ligand similarity. In this respect, rucaparib inhibits nine kinases with micromolar affinity, including PIM1, PIM2, PRKD2, DYRK1A, CDK1, CDK9, HIPK2, CK2, and ALK. In contrast, olaparib does not inhibit any of the sixteen kinases tested. In between, veliparib inhibits only two, namely, PIM1 and CDK9. The differential kinase pharmacology observed among PARP inhibitors provides a plausible explanation to their different cellular effects and offers unexplored opportunities for this drug class, but alerts also on the risk associated to transferring directly both preclinical and clinical outcomes from one PARP drug candidate to another.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1814